Last update 21 Nov 2024

Allogeneic NK Cells(Radboud University Medical Center)

Overview

Basic Info

Drug Type
Natural Killer Cell Therapies
Synonyms
UCB-NK cells(Radboud University Medical Center)
Target-
Mechanism
Natural killer cell replacements
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication
Fallopian Tube CarcinomaRecurrent ovarian cancerRecurrent Primary Peritoneal Carcinoma
Inactive Indication-
Originator Organization
Radboud University Medical CenterRadboud University Medical Center
Active Organization
Radboud University Medical CenterRadboud University Medical Center
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Allogeneic NK Cells(Radboud University Medical Center)
NCT03539406 / CompletedPhase 1IIT
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)
100 Clinical Results associated with Allogeneic NK Cells(Radboud University Medical Center)
Login to view more data
100 Translational Medicine associated with Allogeneic NK Cells(Radboud University Medical Center)
Login to view more data
100 Patents (Medical) associated with Allogeneic NK Cells(Radboud University Medical Center)
Login to view more data
100 Deals associated with Allogeneic NK Cells(Radboud University Medical Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 1
NL
Radboud University Medical CenterRadboud University Medical Center
04 Jun 2019
Recurrent ovarian cancerPhase 1
NL
Radboud University Medical CenterRadboud University Medical Center
04 Jun 2019
Recurrent Primary Peritoneal CarcinomaPhase 1
NL
Radboud University Medical CenterRadboud University Medical Center
04 Jun 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03539406 (INTRO-study, ESGO2024)
ManualManual
Phase 1
Recurrent ovarian cancer
Third line
7
UCB-NK cells ±Fludarabine/Cyclophosphamide
(hbdxvebgvd) = a grade 3 (CTCAE III-IV) rise of liver enzymes, and a grade 3 ileus. lsjsorvadr (bxodwfkbjx )
Positive
10 Mar 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free